Event Calendar
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
MSCA Feedback to Policy 2024 call information session
The Marie Skłodowska-Curie Actions (MSCA) Feedback to Policy 2024 call will open on 25 April 2024. The deadline to submit proposals is 3 September 2024.
To support interested applicants, the European Commission and the European Research Executive Agency (REA) will organise two information sessions to present the policy background of the call and provide practical details to interested organisations. Both information sessions cover the same content.
More information on the call, expected outcomes, indicative timeline and call budget are to be found in this MSCA article and the MSCA call announcement.
Registration for the information session is required here.
The first information session will take place on 25 April 2024, 10.00 - 11.30, CEST and the second opportunity to get more information on the call is on 29 May 2024, 10.00 - 11.30, CEST.
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Event calendar
36 upcoming events view event calendarTestimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
